Nanogel antigen DDS toward overcoming immune resistance of cancer
نویسندگان
چکیده
منابع مشابه
Overcoming immune-cell unresponsiveness in cancer
Despite significant recent progress, cancer immunotherapy efficacies are still limited, since tumors can downmodulate and escape the immune system by various mechanisms. To overcome these limitations, we aimed to identify low molecular weight molecules that can enhance T cell reactivity in the context of otherwise insufficient or suppressive stimulation. In an HTS campaign, 80000 maximal divers...
متن کاملOvercoming cancer immune tolerance and escape.
Although HER2/neu-targeted cancer vaccines have shown initial promise in the adjuvant setting, a therapeutic vaccine remains elusive due to the tumor escape mechanisms of established cancer. As described by Seavey et al. in this issue of CCR, a Listeria-delivered vaccine may help overcome immune tolerance, leading to an effective therapeutic vaccine.
متن کاملP56. A novel cancer vaccine with nanogel-based antigen transporter and sequence-optimised long peptide antigen
Background The limited success of cancer vaccines in clinical could be owing to their low efficacy that can be largely affected by their formulation. Vaccine formulation usually consists of three components, antigen, delivery system, and adjuvant. Recently, long peptide antigen (LPA) has been attracting interest, because (1) one LPA can provide antigen presenting cells (APCs) with multiple T ce...
متن کاملProgress toward overcoming hypoxia-induced resistance to solid tumor therapy
Hypoxic tumors are associated with poor clinical outcome for multiple types of human cancer. This may be due, in part, to hypoxic cancer cells being resistant to anticancer therapy, including radiation therapy, chemotherapy, and targeted therapy. Hypoxia inducible factor 1, a major regulator of cellular response to hypoxia, regulates the expression of genes that are involved in multiple aspects...
متن کاملOvercoming chemotherapy resistance in prostate cancer.
Although treatment for prostate cancer has improved over the past several years, taxanes remain the only form of chemotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). In addition to the promising therapeutic cancer vaccines and newly developed agents targeting androgen receptor signaling, chemotherapy-based treatments will likely continue ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Delivery System
سال: 2020
ISSN: 0913-5006,1881-2732
DOI: 10.2745/dds.35.64